Evidence map›Paper›PMID 35029761›Full record

ArticleActa neurochirurgica2022

Dabrafenib monotherapy for a recurrent BRAFV600E-mutated TTF-1-positive posterior pituitary tumor.

Flavie Grenier-Chartrand, Sami Barrit, Marie Lucie Racu, Sylvie Luce, Julien Spitaels, Niloufar Sadeghi-Meibodi, Laetitia Lebrun, Isabelle Salmon, Florence Lefranc, Olivier De Witte

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Acta neurochirurgica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Updates on management of gliomas in the molecular age.World journal of clinical oncology · 2024
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Flavie Grenier-ChartrandDepartment of Neurosurgery, Erasme Hospital, ULB, Route de Lennik, 808, 1070, Anderlecht, Belgium. flaviegrenier@hotmail.com.ORCID http://orcid.org/0000-0002-9902-8147
Sami BarritDepartment of Neurosurgery, Erasme Hospital, ULB, Route de Lennik, 808, 1070, Anderlecht, Belgium.
Marie Lucie RacuDepartment of Pathology, Erasme Hospital, ULB, Anderlecht, Belgium.
Sylvie LuceDepartment of Oncology, Erasme Hospital, ULB, Anderlecht, Belgium.
Julien SpitaelsDepartment of Neurosurgery, Erasme Hospital, ULB, Route de Lennik, 808, 1070, Anderlecht, Belgium.
Niloufar Sadeghi-MeibodiDepartment of Neuro-Radiology, Erasme Hospital, ULB, Anderlecht, Belgium.
Laetitia LebrunDepartment of Pathology, Erasme Hospital, ULB, Anderlecht, Belgium.
Isabelle SalmonDepartment of Pathology, Erasme Hospital, ULB, Anderlecht, Belgium.
Florence LefrancDepartment of Neurosurgery, Erasme Hospital, ULB, Route de Lennik, 808, 1070, Anderlecht, Belgium.
Olivier De WitteDepartment of Neurosurgery, Erasme Hospital, ULB, Route de Lennik, 808, 1070, Anderlecht, Belgium.
Erasmus Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Posterior pituitary tumors (PPT) expressing thyroid transcription factor-1 (TTF-1) are extremely rare low-grade neoplasms. The recent discovery of BRAF mutations in these tumors offers a potential alternative treatment using targeted therapies. We present the case of a 57-year-old female with recurrent BRAFV600E-mutated TTF-1-positive PPT treated with a BRAF inhibitor monotherapy (dabrafenib) leading to tumor regression. After 18 months of uninterrupted treatment, ongoing radiological tumor regression was observed and the patient remained asymptomatic without any significant adverse event. BRAF inhibitor is potentially a valuable treatment option for recurrent TTF-1-positive PPT with BRAF mutation.

Indexed as

Pituitary NeoplasmsFemaleHumansImidazolesMiddle AgedMutationOximesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafThyroid Nuclear Factor 1BRAF protein, humandabrafenibImidazolesOximesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafThyroid Nuclear Factor 1BRAFV600E mutationDabrafenibPosterior pituitary tumorTTF-1

Identifiers

PMID35029761
OpenAlexW4205491180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.